Systemic Treatment of Brain Metastases from Breast Cancer
Author Information
Author(s): Garrone Ornella, Ruatta Fiorella, Rea Carmen Giusy, Denaro Nerina, Ghidini Michele, Cauchi Carolina, Bareggi Claudia, Galassi Barbara, Merlano Marco C., Rosenfeld Roberto
Primary Institution: Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
Hypothesis
What are the most effective systemic treatments for brain metastases resulting from breast cancer?
Conclusion
The review highlights the importance of a multidisciplinary approach and the effectiveness of new systemic therapies for treating brain metastases from breast cancer.
Supporting Evidence
- Brain metastases from breast cancer represent a significant clinical challenge.
- Patients with HER2-positive and triple-negative breast cancer are at higher risk for brain metastases.
- New systemic therapies, including antibody-drug conjugates, have shown promise in treating brain metastases.
Takeaway
Breast cancer can spread to the brain, and new treatments are helping patients live longer and better. Doctors are using a mix of therapies to fight this problem.
Methodology
This narrative review synthesizes existing literature on the systemic treatment of brain metastases from breast cancer, categorizing data into molecular mechanisms, clinical trial outcomes, and future treatment perspectives.
Potential Biases
Potential biases may arise from the retrospective nature of some studies and the exclusion criteria of clinical trials.
Limitations
The review is limited by the exclusion of patients with known brain involvement from many randomized trials, which affects the evidence base for systemic therapies.
Participant Demographics
The review discusses breast cancer patients, particularly focusing on those with HER2-positive and triple-negative subtypes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website